> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Extends Review of Tecentriq sBLA
- URL: https://www.fdaweb.com/fda-extends-review-of-tecentriq-sbla/
- Published: 2018-09-07T12:00:00.000Z
- Updated: 2026-09-15T00:30:39.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5142290

FDA has extended by three months the review of a Genentech supplemental BLA for Tecentriq (atezolizumab) for use in combination with Avastin (bevacizumab), carboplatin, and paclitaxel in first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). The extension was granted to allow the agency to review additional information it requested, according to the company. The new review action target date is 12/5.

  
In May, FDA granted a priority review based on findings from the Phase 3 IMpower150 trial. In the study, the combination reduced the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type NSCLC, the company says.